Interesting timing. Seems like a purposeful take down to gain control of the company. I've seen this with FORD (not the car company) and it has not turned out well, at least so far. Previous management had been turning the company around and a new CEO took over after constantly taking current management to the woodshed via numerous press releases. A proxy vote later and the new CEO and board were in place. The stock has lost 30% of its value since then, although they promised the shareholders how much benefit they would derive from the new versus the old management. I don't want to see that here.
That part about preparing mentally. If OLED does run, let's say, to $200 or $300, a lot of us will have a large percentage of our stock assets in one stock. What are others' strategies for when that happens? If things look good a few years out, just keep holding even if it becomes half of our portfolio, or do one suggested way which is to rebalance one's portfolio when over-leveraged in one stock?
Sentiment: Strong Buy
No articles on comparing one obesity drug on the market with another. "The most effective,"; the "best," etc., are all stated by supporters of this company's drug, without research to support those assertions. Also, did you mean clinicaltrials dot gov? I sold the stock on the other day. Time will tell if I did the right thing. I'm not a believer.
Right. Let's approve the drug for a use that has not been shown to be effective in clinical trials. We'll do this to save VVUS money. I'm sure the FDA will have no issue with that. Let's start administering the drug to one of your family members without testing the drug in a well-controlled clinical trial.
In what ways or way is Qsymia "the most effective obesity drug on the market"? What data sets are you using to compare the effectiveness of Qsymia to other obesity drugs on the market?
What prevents VIVUS' competitors from engaging in digital marketing, which they might already be doing? Also, VIVUS' request of FDA to be able to market a drug for other than for which it was approved without a clinical trial, based on safety but not on effectiveness, is insane. Perhaps someone can explain what I'm missing. I worked for FDA for 10 years and there is zero way we would approve a drug for a particular purpose without substantiating evidence of such claim.
Do you understand why they suffered a loss? Do you realize that 2014 was a fantastic year for the company and that 2015 will be another great year?
I agree with both of you. I wish I had the cash to buy more at these prices. I got in at 1.05 a while back and watched it run to $3. As usual, I held and here we are. It's a thinly traded stock that has huge moves in either direction. This will correct up, I believe, over the next few days (although not to where it closed yesterday).
Let us know what you think of the battery life. Unless the phone can still function after a full day of heavy use, given the inability to swap batteries it makes no sense for me to upgrade from my S4.
Sentiment: Strong Buy
If the price falls 20% from here, it would be a gift for those who have the cash to buy more.
I have a Galaxy S4 and planned to buy an S6 until I learned that Samsung is going the way of Apple. The S6 will not have a user replaceable battery and will not allow for the use of SD cards. However, there is still hope that the upcoming LG G4 will have user replaceable batteries (it will use SD cards). That phone will hopefully make up for what I predict will be a poor showing in sales by Samsung. There's a lot of Galaxy S4 and S5 users that are ticked off by Samsung removing those features and the waterproof case.
Although I have you on ignore, I decided to see if you perhaps would say something that made sense. No. Back on ignore. I hope you are getting some sort of coaching or counseling in your life. I'm sure it would serve you and those around you (and those of us on the board who do not have you on ignore), well.